FDA-approvedGrowth HormoneReviewed 2026-08-01
Tesamorelin
aka Egrifta
The only FDA-approved GHRH analogue, indicated for HIV-associated lipodystrophy, and one of the few peptides with randomized evidence for visceral-fat reduction and liver-fat improvement.
Mechanism of action
Stabilized GHRH(1-44) analogue that binds pituitary GHRH receptors, restoring physiologic GH pulsatility and raising IGF-1, which preferentially mobilizes visceral adipose tissue.
Doses used in published studies
2 mg subcutaneously once daily in pivotal trials.
These figures describe what researchers administered under supervision. They are reported for accuracy and are not a protocol, recommendation, or substitute for clinical guidance.
Reported benefits
- ~15–18% reduction in visceral adipose tissue over 26 weeks
- Reduced hepatic fat and slowed fibrosis progression in NAFLD substudies
- Improved triglycerides
Risks & unknowns
- Injection-site reactions
- Arthralgia and peripheral edema
- Glucose intolerance
- Requires daily dosing
Legal & regulatory status
FDA-approved 2010 for HIV lipodystrophy. Prescription-only; not approved for cosmetic or anti-aging use.
Check status in your state or country →Key studies
- Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV
The Lancet HIV · 2019